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INTRODUCTION:                                                                                                                   
The oral dosage forms are the most popular way of drug 
administration despite having some disadvantages like 
slow absorption and thus onset of action is prolong. This 
can be overcome by administrating the drug in liquid from 
but, many APIs have limited level of stability in liquid 
form. So, Effervescent tablets acts as an alternative dosage 
form.
1
 As per revised definition proposed to US FDA, 
Effervescent tablet is a tablet intended to be dissolved or 
dispersed in water before administration. In addition to 
active ingredients, it generally contains mixture of 
acids/acid salts and carbonate and hydrogen carbonates 
which release carbon dioxide when mixed with water.
2
 
Effervescence is the evolution of gas bubbles from a 
liquid, as the result of a chemical reaction.                                          
C6H8O7 (aq) + 3NaHCO3 (aq) → Na3C6H5O7 (aq) + 4H2O 
+ 3CO2 (g) ↑ 
Citric acid + Sodium bicarbonate → Sodium citrate + 
Water + Carbon dioxide
 3
 
This reaction occurs in presence of water, even with small 
amount as catalyzing agent, and because water is one of 
the reaction products, it accelerates the rate of reaction, 
leading to difficulty in stopping the reaction. For this 
reason, the whole manufacturing and storage of 
effervescent products is planned by minimizing the contact 
with water.
3 
Alendronate sodium is a BCS class III bisphosphonate, 
used in the treatment of osteoporosis.
5,6
 Which acts as a 
potent, specific inhibitor of osteoclast-mediated bone 
resorption.
4
 Colecalciferol (vitamin D
3
) is a secosterol that 





 Peter C. P. et al., 
examine the possible mechanism for the esophageal 
adverse events reported with alendronate sodium tablets 
and the animal studies showed that under low pH 
conditions alendronate sodium can cause esophageal 
irritation.
8 
This study seeks to formulate  effervescent 
tablet of Alendronate sodium with cholecalciferol, which 
limits the amount of time in which the bisphosphonate is in 
contact with the Oesophageal tissue, thus minimizing the 
risk of irritation
9 
and provide vitamin D3 nutrition during 
bisphosphonate treatment to facilitate normal bone 
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formation and mineralization while minimizing the 
occurrence of or potential for the complications associated 
with vitamin D insufficiency, such as hypocalcaemia and 
osteomalacia.
10
                                           
MATERIAL AND METHODS MATERIALS:  
Alendronate sodium trihydrate was obtained from Apex 
Healthcare Ltd., Ankleshwar (Gujarat), as a gift sample. 
Vitamin D3, Citric acid, PVP-K30, Sodium bicarbonate, 
Sodium saccharine, Malic acid, Maltodextrin, Sodium 
metabisulphite, Boric acid, Sodium benzoate, color and 
flavor were procured from SciTech Specialities Pvt. Ltd., 
Sinnar (Maharashtra). All the APIs and excipients used 
were of analytical grade.                                                                                                                                                                                                                                  
METHODS:                                                                                                                                                        
I. DRUG-EXCIPIENT COMPATIBILITY STUDY:                                                                                  
Drug-Excipient Compatibility Study by FTIR: The IR 
spectrum of drug as well as sample (drug and excipient) 
was recorded using FTIR spectrophotometer (Bruker, 
ALPHA, ECO-ATR) with diffuse reflectance principle. 
Sample was placed in the sample holder and the spectrum 
was scanned over a frequency range 4000– 400 cm-1.11,12
                                                                                                      
Drug-Excipient Compatibility Study by DSC: 
The DSC study was carried out using Mettler Toledo DSC 
822e differential scanning calorimeter with thermal 
analyzer.  The samples (drug and excipients) were heated 
in sealed aluminum pans under nitrogen flow (20 ml/min) 
at a scanning rate of 10°C/min from 0 to 300°C. Empty 
aluminum pan was used as a reference. The heat flow as a 
function of temperature was measured for the samples.
11-13
 
II. FORMULATION DEVELOPMENT:        
Dispense all required materials according to doers-
checkers system. Then shift the materials as per the 
sequence and specified mesh sieves. Mix alendronate 
sodium with citric acid in octagonal blender (20, Anish 
Pharma) & granulated with PVP K30 in rapid mixer 
granulator (20, Anish Pharma). Then it was dried in a 
Fluidize Bed Dryer (20, Anish Pharma). Also blend „B‟ 
was mixed in an octagonal blender.  
Then blend „A‟ & „B‟ were mixed with each other and 
blended with lubrication blend. Final blend was 
compressed with tablet Compression machine (Accura D4, 
Fluidpack) and packed with strip packaging machine (4 
RACK GMP, Vilas Engg.). 




Ingredients                                       Formulation (mg/tab.) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Blend ‘A’           
Sod. alendronate 91.37 91.37 91.37 91.37 91.37 91.37 91.37 91.37 91.37 91.37 
Citric acid 2000.76 1880.8 1763.59 1658.99 1562.56 1531.49 1651.17 1671.7 1653.13 1672.67 
PVP K30 2.15 4.3 6.45 4.3 4.3 4.3 4.3 4.3 4.3 4.3 
Water q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Blend ‘B’           
Sod. bicarbonate 1818.87 1880.78 1939.94 1990.79 2031.32 2144.09 1981.41 2006.03 1983.75 2007.21 
Sod. saccharine 4.3 8.6 12.9 17.2 21.5 17.2 12.9 17.2 15.05 15.05 
Vitamin D3 2 2 2 2 2 2 2 2 2 2 
Malic acid - 4.3 8.6 12.9 17.2 21.5 25.8 21.5 21.5 21.5 
Maltodextrin 172 172 172 172 172 172 172 172 172 172 
Sod. metabisulphite 8.6 8.6 8.6 8.6 8.6 8.6 8.6 8.6 8.6 8.6 
Sunset yellow color 2.15 2.15 2.15 2.15 2.15 2.15 2.15 2.15 2.15 2.15 
Orange flavor 43 86 129 172 215 129 172 129 172 129 
Polomint flavor 4.3 8.6 12.9 17.2 21.5 25.8 25.8 23.65 23.65 23.65 
Lubrication blend           
Boric acid 129 129 129 129 129 129 129 129 129 129 
Sod. benzoate 21.5 21.5 21.5 21.5 21.5 21.5 21.5 21.5 21.5 21.5 
Total 4300 4300 4300 4300 4300 4300 4300 4300 4300 4300 
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               Figure 1: Process flow chart 
Alendronate sodium & Citric acid                                 
through sieve no. 100 & 60 
respectively 
Sodium Bicarbonate 
through sieve no. 60 
Alendronate sodium & Citric acid in a 
Octagonal blender for 10 min. at 15 rpm 
Blend „B‟ in a Octagonal 
blender for 10 min. at 20 rpm 
Using PVP K30 aq. Solution 
in a Rapid Mixing Granulator  
Blend „A‟ in a Fluidize Bed Dryer                
product bed temp. 45⁰ C for 35 min. 
Blend „A‟ & Blend „B‟ in a                                   
Octagonal blender for 15 min. 24 rpm 
 
Mixture of Blend „A‟&„B‟ with Lubrication 
Blend in a Octagonal blender for 5 min. 24 rpm 
Using 25 mm flat punches               
at 4.6 AMP compression force 
In a 40 µ, 2ply aluminium foil having total GSM 138 
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III. EVALUATION OF PRECOMPRESSION BLEND:                                         
1) Angle of repose: 
It was measured by fixed funnel method. The fixed funnel 
method employ a funnel that was secured with its tip at a 
given height „h‟, above graph paper that was placed on a 
flat horizontal surface. Granules were carefully poured 
through the funnel until the apex of the conical pile just 
touches the tip of the funnel. Thus, with „r‟ being the 
radius of the base of the conical pile.
14
                                                                                              
                                            
tan θ = h / r 
Where, θ= angle of repose                                                                                                                        
2) Bulk density: an accurately weighed sample of 
granulation was carefully added to the measuring cylinder 
with the aid of funnel. The level was observed without 
compacting and noted as apparent volume (V0).
14,15
                                                                                                                        
The bulk density was calculated by the formula as given 
below:  
Bulk density=M/ V0 
Where,   M=Mass of powder taken.   V0= Apparent 
untapped volume.                                                                                               
3) Tapped density: After bulk density measurement the 
cylinder was placed on the tapped density tester (ETD 
1060, Electrolab) and was mechanically tapped. The 
cylinder was tapped for 500 times initially and the tapped 
volume (V1) was measured to the nearest graduated units. 
The tapping was repeated for additional 750 times and the 
tapped volume (V2) nearest to graduated units was 
noted.
15
                                                                                                                                                             
The tapped density was calculated by the formula as 
given below: 
                                                         Tapped density= M/ 
V2                                                                                                                                            
Where,  
M= Weight of powder.             V2= Tapped volume (after 
750 taps).                     
4) Carr’s Index: The percentage compressibility of a 
powder is direct measure of the potential of powder arch 





5) Hausner’s ratio: Hausner found that the ratio tapped 
density/bulk density was related to inter particle friction 
as such, could be used to predict powder flow properties. 
The Hausner‟s ratio was calculated by the formula as 
given below:
16
                                                                                                                                                                                                          
                        
 
IV. EVALUATION OF FORMULATION:                                                                                                
1) Tablet Dimensions: 
Ten tablets of each formulation were evaluated for 
thickness and diameter using a calibrated dial caliper.
1
                                                                                        
2) Weight Variation: 
Twenty tablets were selected randomly. Tablets were 
weighed individually and average weight was calculated. 
Then deviation of each tablet from average weight was 
calculated and percent deviation was computed.
 17
                                                        
3) Tablet Hardness:                                                                                                   
The hardness was evaluated using Monsanto 
(VHT1,Veego) hardness tester.
18
                                                                                                    
4) pH of the Solution:                                                                                                                        
pH solution was determined with one tablet in 200 ml of 
purified water at 20 ± 1 °C by using pH meter (HI 2211, 
HANNA), immediately after completing the dissolution 
time
17
                                                                                                                      
5) Solution Time:                                                                                                                                                                              
The solution time is indicating the time required to 
dissolve the tablet in 200ml of water at 17.5 ± 2.5⁰C.18                                                                                                                                  
6) Drug Content Uniformity:                                                                                                     
Drug content analysis of Alendronate sodium: 
Weigh and powder 20 tablets. Weigh accurately a 
quantity of the powder containing about 25 mg of 
Alendronate sodium was taken in a 25 ml volumetric 
flask and dissolved in around 15 ml of distilled water, 
finally filled up to the mark by distilled water to get a 
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sample solution of 1 mg/ml. Then appropriate dilutions 
was done from the sample solution using sodium-1,2- 
napthoquinone-4-sulphonate reagent and 0.01 M NaOH. 
Absorbance of the resulting brown colored solution was 
measured at 525 nm using double beam UV 
spectrophotometer (1600, shimadzu) against a blank.
19
                                                         
Drug content analysis of Vitamin D3:  
Weigh and powder 10 tablets. Weigh accurately about 
12.5 gm of the powder into a 100 ml volumetric flask and 
sufficient amount of Methanol: water (97:3) was added to 
dissolve properly. Then appropriate dilution was done 
and analyzed by HPLC instrument (Shimadzu LC-
2010A) at 264 nm. 
7) Panel Testing (Human Subjects):                                                                                                                       
In vivo taste evaluation carried out on a trained taste 
panel of 5 healthy volunteers with organoleptic sense, 
with their prior consent. On placing the dosage form in 
mouth for 60 seconds, bitterness recorded against pure 
drug.
21
                                                
V. STABILITY STUDIES: The optimized formulations 
sealed in aluminum packaging and kept in the stability 
chamber (CHM-6S, Remi) maintained at 25ºC/60% RH, 
30ºC/65% RH and 40ºC/75% RH conditions for three 
months. The samples of 20 tablets were randomly 
withdrawn on initial stage, after one month and three 
months. These samples were analyzed for the physical 




RESULT & DISCUSSION:                                                                                                                                                                                                                                                                                                     
I. PREFORMULATION STUDY OF Alendronate 
sodium & Vitamin D3:                                                                           
Alendronate is a white, crystalline, nonhygroscopic 
powder. Melting point of ALS observed in between 258-
262
 o
C, it complies the standard. Colecalciferol is a white, 
crystalline, odourless powder. Melting point of 
Colecalciferol observed in between 83-86 
o
C, it complies 
the standard.                                     
II. DRUG-EXCIPIENT COMPATIBILITY STUDY:                                               
DSC Analysis 
 
Figure 2: DSC thermogram of Alendronate sodium 
The DSC thermogram of Alendronate sodium (figure 2), 
showed an endothermic peak in the temperature region 
from 76⁰C to 115⁰C. It is followed by an irregular 
endothermic peak with shoulders at 135.46⁰C that 
corresponds to loss of coordinated and crystal water. The 
third endothermic peak, corresponding to melting of the 
drug is at 261⁰C.  
 
 Fig. 3: DSC thermogram of Vitamin D3 
The DSC thermogram of Vitamin D3 (figure 3), showed 
endothermic peak, corresponding to melting of the drug is 
at 87.78⁰C. 
 
Figure 4: DSC thermogram of Alendronate sodium, 
Vitamin D3 & Excipient mixture 
The DSC thermogram of Alendronate sodium, Vitamin 
D3 & Excipient mixture (figure 4), showed endothermic 
peak, corresponding to melting of the Vitamin D3 is at 
90.24⁰C. It is followed by an irregular endothermic peak 
with shoulders at145.91⁰C that corresponds to loss of 
coordinated and crystal water.  The third endothermic 
peak, corresponding to melting of the Alendronate 
sodium is at 261⁰C. 
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Figure 5: FTIR spectra of Alendronate sodium 
 
Figure 6: FTIR spectra of Vitamin   D3 
      
Figure 7: FTIR spectra of Alendronate sodium: VitaminD3 (1:1) mixture  
 
Figure 8: FTIR spectra of Alendronate sodium, Vitamin D3 & Excipient mixture  
Table 2: Interpretation of FTIR




Observed wave number (cm
-1
) 
1. N-H str. Amine  3300-3500  3480.75,  3481.09 
2. C-H str. Alkenes  3010-3100  3030.50  
3. C-N str. Amine  1070-1150  1126.15, 1125.71, 1072.85   
4. O-H str. Amine  3200-3550  3480.75,   
5. C-C str.  1110-1250 1229.61,  1235.25  
6. C-H str. Alkane  2850-2960- 2914.29, 2958.54, 2917.08     
7. O-H str. Alcohol  3200-3550  3442.22,  3481.09, 3265.43   
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III. EVALUATION OF PRECOMPRESSION BLEND: 
Table 3: Precompression evaluation of blend 
                                                   All values are expressed as mean ± SD (n=3)                                                      
IV. EVALUATION OF FORMULATION:                                               
Preparation of standard calibration curve of Alendronate sodium:  
 
Figure 9: UV- spectrum of Alendronate sodium in distilled water 
Table 4: Absorbance data of Alendronate sodium 
Sr. No. Concentrations  (µg/ml) Absorbance 
1. 10 0.037 
2. 20 0.072 
3. 30 0.109 
4. 40 0.146 
5. 50 0.183 
6. 60 0.222 
                                                  
 
 Figure 10: Calibration curve of Alendronate sodium.
Formula-
tions 
Angle of repose (⁰) Bulk density 
(gm/cc) 





F1 25.56 ± 0.015 0.849 ± 0.001 0.903 ± 0.001 5.98 ± 0.01 1.063 ± 0.002 
F2 25.64 ± 0.01 0.852 ± 0.001 0.906± 0.002 5.96 ± 0.03 1.063 ± 0.003 
F3 25.76 ± 0.0057 0.854 ± 0.002 0.909± 0.002 6.05 ± 0.04 1.064 ± 0.001 
F4 25.84 ± 0.01 0.857 ± 0.002 0.914± 0.001 6.23 ± 0.05 1.066 ± 0.001 
F5 25.78 ± 0.015 0.859 ± 0.001 0.917± 0.003 6.32 ± 0.05 1.067 ± 0.003 
F6 26.08 ± 0.0057 0.859 ± 0.003 0.911± 0.003 5.7 ± 0.12 1.06 ± 0.002 
F7 25.70 ± 0.0057 0.854 ± 0.002 0.909± 0.001 6.05 ± 0.04 1.064 ± 0.002 
F8 25.74 ± 0.01 0.857 ± 0.002 0.914± 0.002 6.23 ± 0.10 1.066 ± 0.001 
F9 25.83 ± 0.015 0.857 ± 0.001 0.911± 0.003 5.92 ± 0.02 1.063 ± 0.001 
F10 26.02 ± 0.0057 0.854± 0.001 0.909± 0.001 6.05 ± 0.04 1.064 ± 0.001 
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Table 5: Evaluation of Thickness, Hardness & Weight variation 
Formulations Thickness (mm) Hardness  (kg/ cm
2
) Wright variation (mg) 
F1 5.95 ± 0.005 6.2 ± 0.057 4.328 ± 0.014 
F2 5.95 ± 0.01 5.7 ± 0.1 4.305 ± 0.005 
F3 5.94 ± 0.015 5.8 ± 0.152 4.3 ± 0.01 
F4 5.96 ± 0.01 6.0 ± 0.152 4.29 ± 0.015 
F5 5.99 ± 0.021 5.7 ± 0.2 4.303 ± 0.006 
F6 6.03 ± 0.015 5.3 ± 0.1 4.336 ± 0.013 
F7 5.97 ± 0.02 5.9 ± 0.057 4.315 ± 0.011 
F8 5.98 ± 0.005 5.9 ± 0.1 4.338 ± 0.005 
F9 5.96 ± 0.01 5.7 ± 0.152 4.325 ± 0.013 
F10 6.0 ± 0.005 5.6 ± 0.057 4.314 ± 0.005 
All values are expressed as mean ± SD (n=3) 
Table 6: Evaluation of chromatograms Vitamin D3Table 7: Evaluation of chromatograms Vitamin D3. 
Average Initial 1
st
 Month (⁰C/RH) 3rd Month (⁰C/RH) 
25/60  30/65 40/75 25/60  30/65 
STD Area 75867.8 75867.8 75867.8 75867.8 75867.8 75867.8 
SPL Area 180596.5 173537 169142.5 162812.5 164843 159485.5 
SPL Wt. 11.8512 12.2451 12.1024 11.9845 12.4456  12.3684 
Tab. 4.6125 4.6014 4.5987  4.6002 4.5941 4.6102 
 
Table 7: Evaluation of Solution time, pH of solution & Drug content 
Formulations Solution time (sec.) pH of solution Drug content (%) 
ALS Vit.D3 
F1 60.33 ± 0.079                                                                                                                        5.1 ± 0.053 99.70 ± 0.080 198.46 ± 0.028 
F2 54.83 ± 0.091 5.04 ± 0.050 99.49 ± 0.069 198.22 ± 0.026 
F3 56.09 ± 0.096 5.42 ± 0.025 99.33 ± 0.060 196.34 ± 0.035 
F4 58.49 ± 0.09 5.54 ± 0.045 99.17 ± 0.083 196.94 ± 0.036 
F5 51.54 ± 0.115 6.03 ± 0.015 99.05 ± 0.092 198.30 ± 0.03 
F6 47.46 ± 0.101 5.85 ± 0.030 99.33 ± 0.063 197.04 ± 0.015 
F7 42.83 ± 0.110 5.68 ± 0.020 99.38 ± 0.081 196.7 ± 0.020 
F8 43.08 ± 0.106 5.58 ± 0.036 99.60 ± 0.072 197.26 ± 0.025 
F9 56.42 ± 0.085 5.52 ± 0.025 99.54 ± 0.057 197.7 ± 0.03 
F10 57.58 ± 0.090 5.7 ± 0.020 99.65 ± 0.029 199.13 ± 0.026 
All values are expressed as mean ± SD (n=3)                                                         
Table 8: Taste Analysis of Formulations 
Formulations Volunteer 
I II III IV V 
F1 Very sour Very sour Very sour Very sour Very sour 
F2 Very sour Sour Sour Very sour Sour 




Sour Very slightly 
sour, good 
Slightly sour 
F4 Good but sweet Good but sweet Good but sweet Good but sweet Good 








F6 after metallic after metallic after metallic after metallic after metallic 
F7 after metallic, after metallic,  
slightly bitter 
after metallic,  
slightly bitter 
after metallic, 
excess  polo 
after metallic,  
slightly bitter 
F8 Sweet ok Sweet Sweet Sweet 
F9 Strong orange 
feel, good 





F10 ok ok ok ok ok 
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Figure 11: Chromatogram of Vitamin D3 Standard solution.                                                                       
V. STABILITY STUDIES:  
Table 9: Evaluation of Formulation (F10) after 1
st 
Month                                                                                                        








% content  
ALS Vit. D3 
25ºC/60% RH Orange  colored 5.7 ± 0.1 58.49 ± 0.09 5.72 ± 0.020 99.21 ± 0.015 184.75 ± 0.025 
30ºC/65% RH Orange  colored 5.7 ± 0.152 58.76 ± 0.091 5.73 ± 0.030 99.13 ± 0.030 182.09 ± 0.032 
40ºC/75% RH Orange  colored 5.7 ± 0.2 58.98 ± 0.115 5.73 ± 0.025 99.01 ± 0.026 177.05 ± 0.028 
All values are expressed as mean ± SD (n=3) 
Table 10: Evaluation of Formulation (F10) after 3
rd
 Month 






pH of solution % content  
ALS Vit. D3 
25ºC/60% RH Orange  colored 5.8 ± 0.115 60.33 ± 0.079 5.75 ± 0.020 98.82 ± 0.025 172.39 ± 0.030 
30ºC/65% RH Orange  colored 5.8 ± 0.152 60.57 ± 0.079 5.76 ± 0.015 98.69 ± 0.026 168.42 ± 0.025 
All values are expressed as mean ± SD (n=3) 
DISCUSSION:                                                                                                                          
The procured sample of Alendronate sodium and Vitamin 
D3 was characterized by organoleptic properties, melting 
point, UV, FTIR and DSC analysis that confirmed the 
purity of the drug. The DSC analysis showed no 
significant shift in the endothermic peak & FTIR analysis 
showed absence of any characteristics peaks of pure drug, 
which confirms the absence of chemical interaction 
between drug and excipients.  Flowability studies 
result indicates good-excellent flow properties of the 
powder mixture. The thickness of the tablet signify 
uniformity and it was due to uniformity in die fill, good 
flow properties, uniform pressure and appropriate punch 
movement. All the formulations are within the limit of 
weight variation. Hardness was found to be in the range of 
5.3 kg/cm
2
 to 6.4 kg/cm
2
.                                                              
Formulations of various effervescent composition show 
variation in the pH of solutions and In-vivo taste 
evaluation by panel test, formulation F10 shows more 
popularity and having better taste than others. Content 
uniform of Alendronate sodium & Vitamin D3 is within the 
limit as per USP specification. It indicates that all 
formulations have the dose uniformity.
23  
 
From the stability study results it was observed that there 
was no significant change in physiochemical properties 
even after storage at various temperature and humidity 
conditions for three months. It may be inferred that there 
was no degradation and change in the formulation. 
CONCLUSIONS:                                                                                                                                       
The Effervescent tablet of Sodium Alendronate and 
Vitamin D3 is a new pharmaceutical formulation to be 
taken orally and offering a considerable advantage: 
avoidance of gastro-intestinal disorders, to the limits of the 
possible. Another aspect of this invention is that the 
absorption of the active ingredient is faster when compared 
to the tablet form; consequently an enhanced 
bioavailability of the active ingredient is probable. As 
compared to the pure drug and marketed tablet, 
effervescent tablet of Alendronate sodium plus Vitamin D3 
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displayed significantly effective in the oral osteoporosis 
treatment in post menopausal women. 
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